Aibotics Therapies, Inc. (AIBT)
| Market Cap | $2.89M+103.1% |
| Revenue (ttm) | $0 |
| Net Income | -$2.09M |
| EPS | $0.01 |
| Shares Out | 890.17M |
| PE Ratio | 0.33 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,208,994 |
| Open | $0.00 |
| Previous Close | $0.00 |
| Day's Range | $0.00 - $0.00 |
| 52-Week Range | $0.00 - $0.02 |
| Beta | 0.21 |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
About AIBT
Aibotics Inc., together with its subsidiaries, engages in the study of psychedelics for the treatment of mental health issues in the United States. It provides psychedelic-enhanced holistic methodologies for the treatment of palliative care, depression, and anxiety. The company was formerly known as Mycotopia Therapies, Inc. and changed its name to Aibotics Inc. in February 2025. Aibotics Inc. is based in Miami, Florida.
$AIBT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AIBT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AIBT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AIBT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AIBT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AIBT from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from AIBT’s recent data — informational, not investment advice
